Phase II Trial of Brentuximab Vedotin for CD30-Positive Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
CME INFORMATION

OVERVIEW OF ACTIVITY
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

Although original data are consistently being presented and published, the flood of information unveiled during a major academic conference is unprecedented and leaves in its wake an enormous volume of new knowledge that practicing oncologists must try to sift through, evaluate and consider applying. Unfortunately and quite commonly, time constraints and an inability to access these data sets leave many oncologists struggling to ensure that they’re aware of crucial practice-altering findings. This creates an almost insurmountable obstacle for clinicians in community practice because they are not only confronted almost overnight with thousands of new presentations and data sets to consider but they are also severely restricted in their ability to review and interrogate the raw findings.

To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets on therapeutic options in the management of non-Hodgkin lymphomas from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts may be applied to routine clinical care. This activity will assist medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES
• Compare the efficacy of consolidation therapy with a single dose of 90Y-ibrutinumomab tiuxetan to that of rituximab maintenance for patients with newly diagnosed follicular lymphoma (FL).
• Examine the utility of early disease progression within 2 years of R-CHOP therapy as a way to identify a subset of patients with FL who are at high risk of death.
• Assess the efficacy and safety of short-term versus long-term rituximab maintenance in FL.
• Evaluate the benefits and risks of brentuximab vedotin for newly diagnosed cutaneous T-cell lymphoma or relapsed or refractory B-cell lymphomas and the effect of CD30 expression on response to this agent.
• Appraise recent clinical findings on the use of front-line lenalidomide with rituximab in mantle-cell lymphoma and of single-agent crizotinib in advanced, chemoresistant ALK-positive non-Hodgkin lymphoma.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJcASH2014/3/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Andrew M Evens, DO, MSc
Professor of Medicine
Chief, Division of Hematology/Oncology
Tufts Medical Center
Director, Lymphoma Program
Interim Director, Tufts Cancer Center
Boston, Massachusetts
Advisory Committee and Contracted Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Seattle Genetics.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodexis Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Seattle Genetics and Spectrum Pharmaceuticals Inc.

Hardware/Software Requirements:
- A high-speed Internet connection
- A monitor set to 1280 x 1024 pixels or more
- Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
- Adobe Flash Player 10.2 plug-in or later
- Adobe Acrobat Reader
- (Optional) Sound card and speakers for audio

Last review date: February 2014
Expiration date: February 2015
To go directly to slides and commentary for this issue, click here.

The rapid integration of novel systemic agents into the management of B- and T-cell lymphomas has the rapt attention of all medical oncologists who see these patients in their practices every day. In the next issue of this series we focus on chronic lymphocytic leukemia (CLL), as Dr Brad Kahl reviews the newly approved type II anti-CD20 monoclonal antibody obinutuzumab and 3 new and exciting small molecules, the Bruton tyrosine kinase inhibitor ibrutinib (now FDA endorsed for mantle-cell lymphoma [MCL] and CLL), the PI3 kinase delta inhibitor idelalisib and ABT-199, an anti-BCL2 pro-apoptotic agent.

Similarly, a future edition of the series will delve into ASH papers on Hodgkin lymphoma, where brentuximab vedotin (BV) continues to shake up traditional paradigms. But for this program we turned our full attention to non-Hodgkin lymphoma (NHL) and asked Dr Andrew Evens, principal investigator of one of the few ongoing major randomized US Cooperative Group NHL trials — ECOG-E2408, a 3-arm Phase II study evaluating bendamustine and rituximab (R) with or without bortezomib followed by R with or without lenalidomide — to provide his perspectives on a number of ASH data sets and what these mean to current practice and future research.

R² (rituximab/lenalidomide) up front in MCL

As has been observed in follicular lymphoma (FL), useful objective responses to this well-tolerated nonchemotherapy regimen are common, and perhaps not surprisingly, in this Phase II study 87% of patients with treatment-naïve MCL derived benefit from therapy. A major Phase III trial (RELEVANCE) compares R² to R-chemotherapy followed by R in previously untreated FL, and a number of studies, including Dr Evens’, are evaluating the equally interesting concept of R² maintenance. However, the sudden and very welcome appearance of ibrutinib in MCL and the obvious logic of evaluating it up front has complicated current discussions regarding new trial designs. While R² involves 2 approved agents and is tempting to consider for older patients and those for whom chemotherapy may be problematic, most investigators, including Dr Evens, are currently conservative about attempting to use the regimen up front in patients with lymphoma, although it is a consideration with refractory disease.
Crizotinib in ALK-positive lymphomas, mainly anaplastic large cell lymphoma (ALCL)

ALK expression is present in more than 50% of patients with ALCL, and an intriguing 2011 New England Journal report revealed the impressive short-term therapeutic activity of crizotinib in 2 individuals with ALK-positive lymphoma. At ASH 2013 we saw a small but stunning new series in which all 9 patients with ALK-positive, refractory ALCL experienced complete responses (CRs) on crizotinib. In addition, 1 partial response was observed among 2 patients with ALK-positive diffuse large B-cell lymphoma (DLBCL) treated with the drug. This important development has Dr Evens and others scratching their heads about how to integrate crizotinib into current lymphoma practice and where it will fit in with the other fairly new kid on the block, BV, as part of new research initiatives.

Maintenance treatment for FL

A fascinating report from the Swiss group comparing R monotherapy followed by short-course (4 doses) or extended (5 years) R maintenance revealed that although the primary endpoint of event-free survival was not statistically different, an impressive prolongation of progression-free survival (PFS) was observed with longer treatment (3.5 years for patients on short maintenance versus 7.4 years with the long-term approach). These intriguing findings seem out of place given that the previously reported results of the ECOG RESORT trial were somewhat unimpressive, and because of this Dr Evens’ personal standard for low-risk disease remains watchful waiting or at most 4 weeks of R with no maintenance. At ASH we also saw more follow-up from the classic PRIMA trial evaluating 2 years of R maintenance after R-chemotherapy in indolent lymphoma, and the 73-month follow-up continues to demonstrate a significant delay in disease progression.

A somewhat surprising Phase II report compared radioimmunotherapy (RIT) consolidation with ⁹⁰Y-ibritumomab tiuxetan to 2 years of R maintenance in patients with newly diagnosed FL responding to R-CHOP. At 3 years, a clear PFS advantage (77% versus 63%; p = 0.044) in favor of R maintenance was observed. Based in part on these data, Dr Evens believes that 2 years of R maintenance remains the standard, but he will still consider RIT consolidation in highly select situations in which a patient’s life plans don’t meld well with regular infusions.

Finally, another report from the now well-publicized National LymphoCare Study in FL provides some solid evidence to back up the collective impression that the approximately 20% of patients who experience relapse in the first 2 years after R-chemotherapy have a poor prognosis. In this analysis of 122 such patients who received R-CHOP up front with a median follow-up of 7 years, the 5-year overall survival rate was approximately 50%. When this is compared to the almost 100%
survival rate for those who did not relapse within 2 years, it seems clear that these individuals should be considered for clinical trials designed to find ways to reverse the rapid downhill trajectory in this situation.

**BV in cutaneous lymphomas and NHL**

Two fascinating papers at ASH reported on Phase II studies evaluating this always-exciting antibody-drug conjugate in several unique lymphoma subsets. In cutaneous disease (primarily mycosis fungoides) 34 of 48 patients obtained objective responses (71%), of which half (35%) were CRs, and in the NHL study 21 of 50 patients with DLBCL (42%) responded, including 16% CRs. What was intriguing and a bit confusing was that activity was observed across a broad range of CD30 expression, including in patients with low or undetectable CD30 expression by standard immunohistochemical staining. Dr Evens believes that while it is possible that BV has off-target antitumor effects, the more likely explanation is that current assays for CD30 are not detecting lower but clinically significant levels of antigen. While this is sorted out, oncologists in practice must consider that useful clinical responses have been seen with BV in patients with a variety of heavily pretreated lymphomas and that perhaps referral for trial participation should be explored for interested individuals regardless of CD30 positivity.

As stated previously, next we check in with Dr Brad Kahl about perhaps the most exciting area of new drug development in oncology — chronic lymphocytic leukemia.

Neil Love, MD
Research To Practice
Miami, Florida
Phase II Trial of Brentuximab Vedotin for CD30-Positive Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

Presentation discussed in this issue


Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (2/12/14)

Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

Duvic M et al.

Proc ASH 2013;Abstract 367.
Background

- Brentuximab vedotin (BV), an antibody-drug conjugate containing an anti-CD30 monoclonal antibody (cAC10), is FDA approved for 2 indications (JCO 2012;30:2183; JCO 2012;30:2190):
  - Treatment of Hodgkin lymphoma after failure of autologous stem cell transplantation (ASCT) or failure of ≥2 prior chemotherapy regimens in ASCT-ineligible patients (overall response rate [ORR]: 75%)
  - Treatment of systemic anaplastic large cell lymphoma (ALCL) after failure of ≥1 prior chemotherapy regimen (ORR: 86%)
- The naked cAC10 antibody was active in CD30+ skin lymphomas (ORR: 70%) (Clin Cancer Res 2009;15:6217).
- **Study objective:** To determine the efficacy and safety of BV in primary cutaneous (pc) CD30+ lymphoproliferative disorders.


Phase II Open-Label Trial Design

<table>
<thead>
<tr>
<th>Eligibility (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pc CD30+ lymphoproliferative disorders*</td>
</tr>
<tr>
<td>Skin lesion expression of CD30</td>
</tr>
<tr>
<td>&gt;10 LyP lesions</td>
</tr>
<tr>
<td>≥1 tumor</td>
</tr>
<tr>
<td>Need for systemic therapy</td>
</tr>
</tbody>
</table>

**BV**

1.8 mg/kg (IV)  
Every 21 days  

Patients who achieved a complete response (CR) received 2 more doses, and those with partial responses (PR) after 8 cycles could receive up to 16 doses.

LyP = lymphomatoid papulosis  
* Including LyP and pc-ALCL or CD30+ mycosis fungoides (MF)

- Patients with CD30+ MF had Stage IB disease or higher and had received ≥1 prior topical or systemic therapies.
- Response criteria were a 50% decrease in lesions for LyP, 50% tumor reduction for pc-ALCL and a 50% decrease in modified skin weighted assessment tool (mSWAT) for MF.
- CD30 pretreatment skin biopsies and serum sCD30 were correlated with response.

## Response by Clinical Diagnosis

<table>
<thead>
<tr>
<th>Primary diagnosis, n (%)</th>
<th>ORR</th>
<th>CR</th>
<th>PR</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients (n = 48)</td>
<td>34 (71%)</td>
<td>17 (35%)</td>
<td>17 (35%)</td>
</tr>
<tr>
<td>MF only* (n = 28)</td>
<td>14 (50%)</td>
<td>2 (7%)</td>
<td>12 (43%)</td>
</tr>
<tr>
<td>LyP only (n = 9)</td>
<td>9 (100%)</td>
<td>5 (56%)</td>
<td>4 (44%)</td>
</tr>
<tr>
<td>pc-ALCL only (n = 2)</td>
<td>2 (100%)</td>
<td>2 (100%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>LyP with MF (n = 7)</td>
<td>7 (100%)</td>
<td>6 (86%)</td>
<td>1 (14%)</td>
</tr>
<tr>
<td>LyP with pc-ALCL (n = 2)</td>
<td>2 (100%)</td>
<td>2 (100%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

* Regardless of whether the lesions had low, medium or high CD30 levels at baseline

- In the intent-to-treat population, patients received at least 1 dose (n = 56)
  - ORR = 61%

Duvic M et al. *Proc ASH* 2013;Abstract 367 (abstract only).

## Time to Response (TTR), Duration of Response (DoR) and Relapse Rate by Clinical Diagnosis

<table>
<thead>
<tr>
<th>Primary diagnosis</th>
<th>TTR (range)</th>
<th>DoR (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MF only (n = 28)</td>
<td>10.5 weeks (3-39)</td>
<td>13.5 weeks (3-56)</td>
</tr>
<tr>
<td>LyP only (n = 9)</td>
<td>3 weeks (3-6)</td>
<td>23 weeks (6-44)</td>
</tr>
<tr>
<td>pc-ALCL only (n = 2)</td>
<td>3 weeks (3)</td>
<td>18 weeks (NR)</td>
</tr>
<tr>
<td>LyP with MF (n = 7)</td>
<td>3 weeks (3-9)</td>
<td>18 weeks (18-44)</td>
</tr>
<tr>
<td>LyP with pc-ALCL (n = 2)</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

NR = not reported

- Relapse rate in all patients with LyP and pc-ALCL (n = 20): 40%
  - TTR: 25 weeks (range: 6-41)
- Relapse rate in responders with MF (n = 14): 36%

Duvic M et al. *Proc ASH* 2013;Abstract 367 (abstract only).
Clinical Outcomes

- Median progression-free survival:
  - From diagnosis: 9.7 years
  - From first dose: 1.68 years
- Soluble CD30 levels from baseline to end of study differed significantly among the patients who achieved a CR compared to those with a PR or stable disease.
  - $p = 0.036$

Duvic M et al. *Proc ASH* 2013;Abstract 367 (abstract only).

Author Conclusions

- This Phase II trial demonstrated that BV is active in patients with MF with an ORR of 50%, irrespective of the level of CD30-positive expression.
- For patients with CD30-positive pc-ALCL, the ORR was 100%.
- In all evaluable patients with LyP, BV elicited activity.
  - ORR: 71%
  - CR: 36%

Duvic M et al. *Proc ASH* 2013;Abstract 367 (abstract only).
Investigator Commentary: Results from a Phase II Trial of BV in CD30-Positive Cutaneous T-Cell Lymphomas and Lymphoproliferative Diseases

A conclusion of this Phase II study is that BV is active irrespective of the intensity of CD30 levels. Whether the patient has a 1% or 90% level of CD30 expression, BV elicits activity. This probably has a lot to do with the sensitivity of the currently commercially available antibodies used for IHC stains. From a clinical point of view, the troubling aspect is that if you use the available antibodies or assays, you will have patients with disease recorded as CD30-negative — not even with 1% expression — that will respond to this agent.

Because of this, ongoing studies are investigating BV in patients with CD30-negative disease. This is necessary because CD30 positivity is not emerging as an important marker for response. That being said, my bet is that BV will result in a lower response rate in CD30-negative versus positive disease.

*Interview with Andrew M Evens, DO, MSc, February 12, 2014*